Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
JoVE Journal
Immunology and Infection

A subscription to JoVE is required to view this content.
You will only be able to see the first 20 seconds.

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
 

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Article doi: 10.3791/50662
August 1st, 2013

Summary August 1st, 2013

Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe vaccines to combat human pathogenic arenaviruses.

Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
simple hit counter